Build status - In Progress

A5364: A Phase I Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption

Recruiting
99 years or below
All
1 Location

Brief description of study

The main purpose of this study is to see if it is safe to give people 10-1074-LS and 3BNC117-LS and to see if these study drugs cause any side effects. We also want to see how the study drugs affect the level of HIV in the blood when you are not taking your regular drugs to control HIV for an extended period of time. This extended period of time when you are not taking your regular drugs to control HIV is referred to as analytical treatment interruption (also called ATI).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 11 Jan 2023. Study ID: 851543

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center